Results 91 to 100 of about 92,290 (306)

Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons, Nuria Guillen, Jordi Sarto, Neus Falgàs, Sergi Borrego‐Écija, Diana Esteller‐Gauxax, Magda Castellví, Adrià Tort‐Merino, Agnès Pérez‐Millan, Anna Antonell, Josep M. Augè Fradera, Gerard Piñol, Iolanda Riba, Anna Carnes‐Vendrell, Marta Cullell, Maria Teresa Osuna, Lorena Bajo, Teresa Romero, Eva Bonjoch, Joan Bello, Susana Fernández, Marta Balagué, Isabel Gómez‐Ruiz, Anuncia Boltes, Claustre Pont, Raquel Cuevas, Sara Carrillo, Laura Iglesias, Teresa Maria Casadevall Codina, Lorena Grau Guinea, Fernando Jose Espada, Raquel Sánchez‐Valle, Mircea Balasa, Albert Lladó   +33 more
wiley   +1 more source

The patient's journey: living with diabetes

BMJ, 2006
When I was diagnosed as having type 1 diabetes in 1984 at the age of 12 it came as a shock. I didn't know it at the time but all the signs were there: in the weeks before the diagnosis I had been losing a lot of weight, I was drinking far more than normal, I often felt unwell, and I recall my mother commenting on my constant mood swings. Eventually she
openaire   +3 more sources

Before-after evaluation of patient length of stay in a rehabilitation context following implementation of an electronic patient journey board

, 2020
PURPOSE: To investigate whether the installation of electronic patient journey boards in an inpatient adult rehabilitation centre in Victoria, Australia, is associated with shorter lengths of stay for admitted adult rehabilitation patients.
Khanna, Sankalp, Reeson, Andrew, Rolls, David, Jayasena, Rajiv, Lloyd, Nicola, Hakkennes, Sharon, McCormick, Christopher   +6 more
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

From Fear to Hope: How Communication Transformed Our Pregnancy Journey A Personal Narrative on the Critical Role of Healthcare Communication in Patient Experience

This article emphasises the transformative potential of compassionate healthcare communication, particularly in the context of pregnancy loss. This personal narrative illustrates how varying communication approaches can significantly alter patient ...
P, Valan., Venugopal, Pulidindi
core   +1 more source

Aquaporin‐4 in Narcolepsy Type 1: Investigation of Perivascular Fluid Movement in Sleep Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Narcolepsy type 1 (NT1) is caused by the loss of hypocretin‐1 leading to excessive daytime sleepiness and cataplexy. Additionally, disrupted nighttime sleep has become an increasingly recognized feature of NT1. As the glymphatic fluid movement has been linked to sleep architecture, we investigated cerebrospinal fluid (CSF) Aquaporin‐4 (AQP4 ...
Jonas Ranke, Petra Steinacker, Steffen Halbgebauer, Patrick Oeckl, Geert Mayer, Markus Otto   +5 more
wiley   +1 more source

Experiences and perspectives on the GIST patient journey

, 2012
Nancy Macdonald1, Ari Shapiro1, Christina Bender2, Marc Paolantonio2, John Coombs21Flince Research + Design, New York, NY, 2Novartis Pharmaceuticals, East Hanover, NJ, USAPurpose: The tyrosine kinase inhibitor (TKI) imatinib has improved outcomes for ...
Shapiro A, Bender C, Paolantonio M, Macdonald N, Coombs J   +4 more
core  

Visualization of a baseline patient journey.

, 2023
BackgroundHealthcare professionals caring for chronically ill patients increasingly want to provide patient-centered care (PCC). By understanding each individual patient journey, they can significantly improve the quality of PCC.
Daniëlle van Bijnen (15572461), Bert R. Meijboom (9647662), Frederik H. Dibbets (15572458), Vincent J. T. Peters (9647659), Vera K. Maas (15572455)   +4 more
core   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Review and expert opinion on MAFLD, oxidative stress and multifunctional management

Drugs in Context
Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most widespread and emerging chronic liver disease worldwide, with increasing prevalence rates also in the Asia-Pacific region.
Francesco Angelico, Diana Alcantara-Payawal, Rafiz Abdul Rani, Norlaila Mustafa, Nuntakorn Thongtang, Roongruedee Chaiteerakij, Chalermrat Bunchorntavakul, Apichard Sukonthasarn   +7 more
doaj   +1 more source